Press Releases Ypsomed Group

Burgdorf / IndianapolisEli Lilly and Company (NYSE: LLY) and Ypsomed (SWX: YPSN) announced today a non-exclusive, global agreement to advance an automated insulin delivery system as part of Lilly’s connected diabetes solutions. Under the terms of the agreement, Lilly will commercialize the system, which is currently in development and will include an insulin pump developed and manufactured by Ypsomed.

Eli Lilly Partnering - Simon Statement - INT-en

Ypsomed’s insulin pump has been marketed in Europe since 2016. Available in 21 countries as the mylife YpsoPump, this pump stands out for its small size and its unique, icon-based touch screen. Lilly will commercialize a version of this insulin pump, along with continuous glucose monitoring (CGM) and automated insulin delivery technology, in the United States and Europe. This pump will use pre-filled insulin cartridges for Lilly’s rapid-acting insulins.

“Lilly is committed to delivering solutions that meet the needs of the diabetes community and providing more options to help them manage their diabetes,”

said Marie Schiller, Vice President of Product Development for Connected Care and Insulins at Lilly.

“People who use insulin, along with their healthcare providers, need simple, effective tools that lead to improved outcomes, and Ypsomed is developing an automated insulin delivery system with several exciting features that can help meet that need.”

Ypsomed plans to submit a version of the YpsoPump for clearance to the U.S. Food and Drug Administration for use in automated insulin delivery in 2022. If cleared, Lilly will have exclusive rights to commercialize the pump in the U.S.

“We are thrilled to partner with Lilly to bring our insulin pump to the United States and deliver improved outcomes to people with diabetes through connected solutions,”

said Simon Michel, CEO of Ypsomed.

“Managing diabetes with insulin is already complex enough, so we developed this insulin pump to be easy to learn and easy to operate. Our goal is to support people living with diabetes through app-centric insulin management, CGM data and advanced algorithms. Partnering with Lilly to bring a holistic platform to market is an important next step in this journey that started in 1984 by introducing the world’s first micro insulin pump to the market.”

Telephone conference calls and online presentations

Ypsomed’s CEO Simon Michel is available today at 10.00 CET (in German) and at 16.00 CET (in English) on a conference call giving insight about the agreement and answering questions from analysts, investors and media.

Access at 10.00 CET:

Join the call:  +41 58 262 07 11
Access code 460098 to ask questions in German
Conference Web Access

Access at 16.00 CET:

Join the call:  +41 58 262 07 22
Access code 384628 to ask questions in English
Conference Web Access

Thomas Kutt
Head of Investor Relations
Ypsomed Holding AG

Eli Lilly Contacts

Maggie Pfeiffer, Lilly Media
+1 (317) 650-5939 / monson_maggie@lilly.com

Kevin Hern, Lilly Investors
+1 (317) 277-1838 / hern_kevin_r@lilly.com

About Eli Lilly and Company

Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at lilly.com and lilly.com/newsroom.

返回